
    
      Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg
      compared to Eplerenone in patients with essential hypertension.

      Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg
      compared to 2.5 mg.
    
  